Inhibikase Therapeutics (IKT) Cash & Equivalents Growth (3y) (2023 - 2026)
Powered by 
Analysis
Inhibikase Therapeutics (IKT) Cash & Equivalents Growth (3y) (2023 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | -15.41% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 8.23% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 47.78% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -23.18% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 14.34% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 37.45% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | -27.97% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -3.85% |
| 10 | Inhibikase Therapeutics | 435.56 Mn | 276.54 Mn | - | 153.97% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 153.97% |
| Mar 31, 2026 | 132.26% |
| Dec 31, 2025 | 168.55% |
| Sep 30, 2025 | 87.76% |
| Jun 30, 2025 | 34.14% |
| Mar 31, 2025 | 26.12% |
| Dec 31, 2024 | 11.50% |
| Sep 30, 2024 | -72.69% |
| Jun 30, 2024 | -59.61% |
| Mar 31, 2024 | -37.44% |
| Dec 31, 2023 | -13.07% |
| Sep 30, 2023 | 872.30% |
| Jun 30, 2023 | 525.49% |
| Mar 31, 2023 | 570.17% |